RAPT Therapeutics' oncology segment is dedicated to the discovery and development of novel therapies targeting cancer. The lead oncology drug candidate, FLX475, an oral small molecule CCR4 antagonist, is currently under investigation in a Phase 1/2 clinical trial, both as a monotherapy and in combination with pembrolizumab, for patients with advanced cancer. This segment focuses on disrupting the tumor microenvironment by inhibiting CCR4, thereby reducing the recruitment of immunosuppressive cells and enhancing the efficacy of other cancer treatments. RAPT's research efforts also include identifying and validating new oncology targets, developing innovative drug candidates, and conducting preclinical and clinical studies to assess the safety and efficacy of these therapies. The ultimate goal is to provide new treatment options for patients with difficult-to-treat cancers and improve patient outcomes.

The inflammatory disease segment at RAPT Therapeutics focuses on developing targeted therapies for patients with unmet needs in inflammatory conditions. The lead inflammation drug candidate, RPT193, is a C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. This approach aims to reduce inflammation and alleviate symptoms in diseases such as atopic dermatitis and asthma. RAPT's research and development activities in this segment include identifying novel targets, developing potent and selective small molecule inhibitors, and conducting preclinical and clinical studies to evaluate the safety and efficacy of these therapies. The company is committed to advancing innovative treatments that can improve the lives of patients suffering from chronic inflammatory diseases by addressing the underlying mechanisms of inflammation and providing targeted therapeutic interventions.